Novagali eye Treatment for Vernal Keratoconjunctivitis (VKC) Successful in Phase III Trial novagali眼治疗春季角结膜炎( vkc )成功地在第三阶段试验
Tuesday, April 10th, 2007 周二, 2007年4月10日Israeli-French drug development company Novagali SA, which was founded on the basis of research conducted by Prof. Simon Benita of the Hebrew University of Jerusalem, has successfully completed European Medicines Agency (EMEA) Phase III clinical trials of its eye treatment for Vernal Keratoconjunctivitis (VKC)..以色列-法国药物开发公司novagali SA服务,这是基础上建立的进行的研究教授西蒙贝妮塔的耶路撒冷希伯来大学,成功地完成了欧洲药品管理局( EMEA )来第三阶段的临床实验,其眼治疗春季角结膜炎( vkc ) ..
































